• Flexible Phage Nanofibers Enhance Rare Cell Capture for Canc

  2026-04-13

  This study introduces a novel affinity surface using flexible bacteriophage nanofibers functionalized with specific aptamers and tethered to magnetic beads, dramatically improving the selective isolation and profiling of rare circulating tumor cells (CTCs) from whole blood. The findings have direct implications for precise cancer subtyping and highlight how viral mechanical properties can be engineered to enhance both binding affinity and anti-fouling in clinical diagnostics.

• Optimizing Mouse Genotyping: Lysis Buffer SKU H1002 in Pract

  2026-04-13

  This article examines the scientific and operational advantages of 'Lysis buffer, components of the rapid genotyping kit for mouse tail' (SKU H1002) for mouse tissue DNA extraction. Through scenario-driven Q&A, we address common pain points in genotyping workflows and illustrate how SKU H1002 supports robust, reproducible results. Practical guidance is provided for researchers seeking reliable genomic DNA release and efficient proteinase K digestion.

• Eltanexor (KPT-8602): Reliable XPO1 Inhibition for Cancer As

  2026-04-12

  This article addresses common experimental challenges in cell viability and cytotoxicity assays, illustrating how Eltanexor (KPT-8602), SKU B8335, delivers reproducible, data-backed solutions. By exploring real laboratory scenarios, it demonstrates the practical benefits and validated performance of this second-generation XPO1 inhibitor for acute myeloid leukemia, chronic lymphocytic leukemia, and colorectal cancer research.

• Perphenazine (SKU B6157): Reliable Dopamine D2 Antagonist fo

  2026-04-12

  This article addresses key experimental challenges in cell viability, cytotoxicity, and neuropharmacology assays, emphasizing the use of Perphenazine (SKU B6157) as a rigorously characterized dopamine D2 receptor antagonist. Through scenario-driven Q&A, it provides actionable guidance on assay optimization, data interpretation, and product selection, highlighting APExBIO's commitment to reproducibility and scientific rigor.

• Applied Workflows with Recombinant Human Growth Hormone (GH)

  2026-04-11

  Unlock the full potential of Recombinant Human Growth Hormone (GH) in advanced cell proliferation and bone growth studies. This guide translates the latest mechanistic insights—especially the IGFBP2-THBS1-IGF-1 axis—into practical lab protocols, troubleshooting, and innovation-driven research strategies.

• RapaLink-1: Third-Generation mTOR Inhibitor for Dormancy & T

  2026-04-11

  RapaLink-1 stands out as a third-generation mTOR inhibitor, enabling unprecedented control over mTORC1 signaling for both cancer and embryonic dormancy research. Its bivalent mechanism overcomes resistance mutations and delivers robust, reproducible results in cell and animal models.

• Imipramine (hydrochloride): Technical Guide for Lab Applicat

  2026-04-10

  Imipramine (hydrochloride) is a tricyclic antidepressant mainly used in research on major depression and enuresis, acting as a serotonin and norepinephrine transporter inhibitor. This guide provides actionable parameters and workflow advice for laboratory use. It is not intended for clinical or in vivo diagnostic applications beyond validated rodent models.

• I-BET-762: Selective BET Bromodomain Inhibitor for Inflam...

  2026-04-10

  I-BET-762 is a highly selective BET bromodomain inhibitor used to study epigenetic regulation, anti-inflammatory mechanisms, and ferroptosis in preclinical models. This article details its nanomolar potency, validated biological targets, and optimized parameters for research workflows.

• DAPT (GSI-IX): Strategic Leverage of γ-Secretase Inhibiti...

  2026-04-09

  This thought-leadership article explores DAPT (GSI-IX) as a selective γ-secretase inhibitor, integrating mechanistic insight with actionable strategies for translational researchers. We dissect the molecular basis of γ-secretase and Notch pathway blockade, validate experimental applications in neurodegeneration, cancer, and advanced organoid models, and position DAPT as a critical tool for innovative disease modeling and therapeutic development. Drawing on recent peer-reviewed findings—including the generation of functional hepatobiliary organoids from hiPSCs—this piece moves beyond standard product descriptions, offering a roadmap for leveraging DAPT in the evolving landscape of biomedical discovery.

• I-BET-762: High-Affinity BET Inhibitor for Epigenetic & I...

  2026-04-08

  I-BET-762 is a potent, selective BET bromodomain inhibitor used in preclinical models for inflammation and cancer biology research. This article details its nanomolar binding affinity, mechanism of transcriptional regulation, and evidence for anti-inflammatory and ferroptosis-enhancing effects.

• T-5224: Advanced AP-1 Pathway Inhibition for Translationa...

  2026-04-08

  Discover how T-5224, a selective C-Fos/AP-1 inhibitor, enables precise modulation of inflammation and osteoclastogenesis in translational arthritis and neuroinflammatory models. This article delves into unique mechanistic insights and explores expanded applications beyond conventional workflows.

• DAPT (GSI-IX): Selective γ-Secretase Inhibitor for Notch ...

  2026-04-07

  DAPT (GSI-IX) is a highly selective γ-secretase inhibitor widely used in Alzheimer's disease and cancer research. Its well-characterized mechanism blocks Notch signaling and amyloid precursor protein processing with nanomolar potency, making it a reference compound for studies on neurodegeneration, angiogenesis, and cell fate. This article presents verified facts, recent benchmarks, and practical parameters for advanced biomedical workflows.

• I-BET-762: Translating BET Bromodomain Inhibition into Ne...

  2026-04-07

  This thought-leadership article unpacks the mechanistic depth and translational promise of I-BET-762, a highly selective BET bromodomain inhibitor from APExBIO. Integrating new evidence on ferroptosis and transcriptional regulation, the article guides translational researchers in deploying I-BET-762 for precision epigenetic modulation in inflammation and cancer biology. Expanding beyond traditional product descriptions, it offers a strategic, actionable roadmap for leveraging I-BET-762 in next-generation preclinical models and combinatorial therapeutic strategies.

• Mianserin Hydrochloride: Mechanism, Evidence & Research U...

  2026-04-06

  Mianserin Hydrochloride is a tetracyclic antidepressant and non-selective 5-HT2 receptor antagonist with validated efficacy in depression and emerging antipathogenic roles. Its distinct mechanism does not involve monoamine reuptake inhibition, and it forms cytotoxicity-enhancing complexes with β-cyclodextrin. This article details its mechanism, benchmarks, and practical research integration.

• I-BET-762 (SKU B1498): Reliable BET Inhibition for Advanc...

  2026-04-06

  This article addresses recurring challenges in cell viability, proliferation, and cytotoxicity assays, illustrating how I-BET-762 (SKU B1498) empowers researchers with reproducible, data-driven results. Drawing from recent peer-reviewed evidence and practical workflows, it demonstrates the unique value of I-BET-762 as a selective BET bromodomain inhibitor in mechanistic cancer and inflammation research. The discussion is tailored for biomedical scientists seeking robust, validated BET inhibition in complex experimental setups.

15535 records 1/1036 page Next 12345 下5页 Last page